Objective: We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not.
Introduction
We recently reported results of a pilot trial, testing the feasibility of enterally administering D-penicillamine to preterm neonates during the first 14 days after birth. 1 That trial was carried out as a step toward estimating the benefits and risks of using this treatment to diminish the incidence and/or severity of retinopathy of prematurity (ROP). ROP is a common retinal neovascular disorder of premature infants, which sometimes heals spontaneously with no sequelae, but sometimes progresses to partial or total loss of vision. 2, 3 The National Eye Institute estimates that ROP affects 14 000 neonates each year in the USA, with 400 to 600 of these developing complete blindness. 4 The incompletely vascularized retinas of preterm neonates put them at risk for developing ROP. Damage in the avascular retina is thought to induce production of vasogenic factors such as vascular endothelial growth factor (VEGF), which stimulate neovascularization near the retinal surface. [5] [6] [7] The neovascularization can be followed by fibrosis and subsequent scar contraction, leading to retinal detachment. 8, 9 Reactive oxygen species are candidates for causing the initial retinal injury.
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Penicillamine (3-mercapto-D-valine) is a chelator of pro-oxidant heavy metals and thus has the potential to reduce the amount of free radical activity. D-Penicillamine can also decrease the bioavailability of VEGF by reducing its disulfide bonds. [10] [11] [12] [13] [14] [15] Lakatos et al. 16 reported a low incidence of ROP among preterm infants treated with D-penicillamine. 17 A recent Cochrane review by Phelps et al. 18 concluded that insufficient data exist for recommending D-penicillamine prophylaxis in clinical practice, and suggested that more studies be accomplished to test this promising approach. In our previous pilot trial, 1 five extremely low birth weight preterm neonates were treated enterally with a 14-day course of Dpenicillamine, using the doses and dosing intervals reported by Lakatos et al. 16, 17 In those five subjects, we judged that the treatment was feasible to administer, because no doses were withheld in any of the subjects and no toxicities were observed. A second study was performed to quantify blood and urine concentrations of D-penicillamine at various intervals following dosing of 10 preterm neonates. 19 The present analysis is a comparison of the outcomes of these 15 patients treated with Dpenicillamine, with 34 preterm infants of similar gestational age and birth weight who were cared for in the same NICU after the conclusion of the first (feasibility) study but before the start of the second (pharmacokinetics) study.
Methods

Study participants
Data were analyzed from the 15 neonates who participated in either of the two D-penicillamine studies in 2005 and 2006 at the McKayDee Hospital Center in Ogden, UT. 1, 19 These two studies had identical eligibility criteria, namely a birth weight of <1000 g or a gestational age at birth p29 weeks, lack of a 'lethal' congenital anomaly and expected to survive more than a few days, as assessed by attestation of the attending neonatologist. 1, 19 As a comparison group, data were obtained from records of all neonates who also met these eligibility criteria but were born after the conclusion of the first study but before the beginning of the second study. The Intermountain Healthcare Institutional Review Board approved both ROP study protocols and the retrospective outcomes analysis, and parents of all of the D-penicillamine recipients signed informed consent documents.
Study drug preparation 3-Mercapto-D-valine was purchased in 250 mg capsules from the manufacturer (Merck & Co., Whitehouse Station, NJ, USA) as Cuprimine. The excipients included D&C YELLOW No. 10, gelatin, lactose, magnesium stearate, titanium dioxide and iron oxide. The capsules were compounded into a suspension (by JTH) as follows: a 100 mg/ml solution was made by using 10 Cuprimine 250 mg capsules, emptying the powder into a mortar, making certain it was a fine powder with no clumps. To this, 5 ml of Ora-Plus (Paddock Labs, Minneapolis, MN, USA) was added to make a uniform paste. To this, 20 ml of sterile water was added, mixing until all drug appeared to dissolve into a uniform suspension. In preliminary studies, the suspension was stored for up to 30 days in the research pharmacy refrigerator, with weekly removal of aliquots for bacterial culture, pH determination and refractive index measurement. No microbial contamination, pH change or apparent degradation was detected over this period. The suspension for clinical use was poured into an amber bottle with proper labeling of drug name, concentration, recipe and statements of 'Shake Well' and 'Refrigerate', and with an expiration of 30 days refrigerated.
ROP examinations and ROP surgery
The initial retinal examinations took place at 31 to 33 weeks postconceptional age or 4 to 6 weeks postnatal age, whichever was later. The examinations were all performed using binocular indirect ophthalmoscopy and a 28 D lens. The follow-up examination schedule was determined by the results of the examinations. Examinations were performed at least weekly if vessels were in zone I or if there was stage 2 or 3 retinopathy in zone II. For all other infants, examinations were performed at least every 2 weeks until zone II was completely vascularized. Examination frequency was at the examiner's discretion for infants with vessels in zone III.
Examination results were recorded on a standardized form at the time of the examination. Examination results were recorded using the ICROP classification as expanded and clarified by the International Committee for the Classification of ROP. 20 This included (in addition to the original ICROP nomenclature) documentation of 'pre-plus disease' and 'aggressive posterior ROP (AP-ROP)' if present.
The study endpoint of 'ROP requiring surgery' was defined as retinopathy of a severity equal to or greater than any one of the following: (1) threshold disease as defined by the CRYO-ROP study; 21 (2) type 1 pre-threshold disease as defined by the ETROP study; 22 and (3) aggressive posterior ROP as defined by the International Committee. 20 The treatment modality and parameters (type of laser used, number and size of spots, etc.) were at the surgeon's discretion.
NICU policy for oxyhemoglobin saturation limits, by continuous pulse oximetry monitoring During the time these studies were carried out (1 March 2005 through 16 June 2006), the NICU policy for the lower and upper limits of oxyhemoglobin saturations was consistent. Specifically, the policy called for an increase in FiO 2 if the transcutaneous oxyhemoglobin saturation decreased below 84% and called for a decrease in FiO 2 if the saturation was above 94%. Accordingly, the alarms on the oxyhemoglobin saturation monitors of all 49 patients were set at 84 and 94%.
Statistical considerations
Data were entered into Microsoft Excel 2003 and imported into SPSS 14.0 for Windows for analysis (Chicago, IL, USA). Descriptive statistics were calculated using standard methods. Comparisons between infants receiving vs not receiving D-penicillamine were conducted using independent samples t-tests for continuous variables and Fisher's exact tests for dichotomous variables. Where parametric assumptions for continuous measures were not met, the Wilcoxon rank-sum test was used. All tests were two-sided and used an a´of 0.05.
Results
During the months of March through June 2005 and February through June 2006, the families of 17 eligible NICU patients were contacted to inquire whether they were interested in learning about the first (feasibility) or the second (pharmacokinetics) ROP studies. Fifteen of the 17 gave written consent for their neonate to participate and two did not. All 15 where consent was given were enrolled into the study and none were withdrawn after enrolling. During the months of July 2005 through January 2006 (when no ROP studies were enrolling at this site), 34 neonates who met the entry criteria for the ROP studies were cared for. These 34 constituted the comparison group for this study. A total of three patients were considered ineligible for study. One was born during the time the second (pharmacokinetics) study was enrolling patients. This patient had hypoplastic right ventricle and weighed 943 g at 28.6 weeks gestation, and was not eligible for study because of what was judged to be a lethal congenital abnormality. Indeed this patient died. The other two were born during the control period (after the first D-penicillamine study had finished and before the second had begun). One had severe hydrops and was delivered at 28 weeks gestation, and the other had severe birth asphyxia and was delivered at 23 weeks gestation, and intensive care support was withdrawn in both before 24 h after birth. These two patients were not included as part of the non-recipient (control) group.
The 15 D-penicillamine recipients were delivered at 26.6±2.2 weeks gestation (mean±s.d.) with birth weights of 849±187 g. The 34 non-recipients were delivered at 26.5±1.8 weeks gestation with birth weights of 887±222 g. The gender distribution of the Dpenicillamine recipients (66% male) and the non-recipients (62% male) was similar. Of the 15 D-penicillamine recipients, 14 survived. The one death was on the 14th day of life with a pulmonary hemorrhage and presumed late-onset bacterial sepsis. Of the 34 non-recipients, 30 survived. The four deaths occurred on the 1st, 2nd, 6th and 37th day of life. The three early deaths all involved hemorrhage (two intraventricular hemorrhage (IVH) and one generalized bleeding), and the death on day 37 was associated with late-onset sepsis.
Among the 14 D-penicillamine recipients who survived, three (21%) developed ROP, whereas among the 30 non-recipient survivors, 18 (60%) developed ROP (P ¼ 0.01). However, the reduction in ROP was limited to those with stage I and stage II ROP, because all three D-penicillamine recipients who developed ROP went on to have stage III ROP and laser surgery. This incidence of laser surgery (3/14, 21%) was similar to the incidence among the non-recipients (7/30, 23%). The three D-penicillamine recipients who required laser surgery were delivered at 22 2/7 to 25 3/7 weeks gestation, weighing 530 to 620 g, and the seven nonrecipients who required laser surgery were delivered at 23 4/7 to 26 2/7 weeks gestation weighing 400-1055 g (P ¼ NS for both comparisons) ( Table 1) .
The highest recorded creatinine, highest recorded direct bilirubin and highest recorded indirect bilirubin were similar among the D-penicillamine recipients and the non-recipients (Table 2) . Similarly, the proportion of patients who developed thrombocytopenia (platelet count <150 000/ml), severe thrombocytopenia (<50 000/ml) or neutropenia (<1000/ml) were similar in the D-penicillamine recipients and the non-recipients.
The increases in weight from the time of birth to days 14, 28 and 56 were similar among the D-penicillamine recipients and the non-recipients. The number of erythrocyte transfusions received in the NICU was not higher, and the blood hemoglobin concentration at the time of hospital discharge was not lower, among the Dpenicillamine recipients. The proportion of patients discharged home on supplemental oxygen was not higher among the Dpenicillamine recipients (Tables 3 and 4) .
Discussion
The annual number of new cases of ROP and the annual number of new cases of blindness from ROP appear to be increasing worldwide. 4, 23 This is likely because of the constantly improving ability of modern neonatology to save smaller and more immature neonates. Some of the recent attempts to reduce the incidence of ROP have not been particularly successful, 24, 25 with the exception of efforts to keep transcutaneously measured oxyhemoglobin saturations below the mid-90% range. 26 Two new potential means of preventing ROP seem to have biological plausibility: prophylactic administration of inositol 27, 28 and prophylactic administration of D-penicillamine. 1, [16] [17] [18] Large, multicentered, randomized, placebo-controlled trials are needed to provide accurate estimates of the benefits and risks of these strategies for preventing ROP and improving long-term vision. However, before granting agencies are likely to fund those efforts, they will probably want to see not only biological plausibility, but also pilot studies showing feasibility, reasonable preliminary safety profiles and perhaps even promising efficacy estimates based on early clinical trials. The present analysis was undertaken as a means of judging whether to invest further effort toward a placebocontrolled, D-penicillamine ROP prevention trial. Using our two recent open-labeled, non-randomized trials, 1, 19 we compared the outcomes of 15 D-penicillamine recipients with 34 contemporary controls. We found a significantly lower incidence of ROP among the D-penicillamine recipients (21 vs 60%, P ¼ 0.01). However, the benefit seemed to be limited to eliminating the milder cases.
Reducing the odds of developing stage I and stage II ROP, but not reducing the odds of developing the more advanced stages does not appear to be a particularly useful outcome. However, in a small study such as this, particularly in a non-randomized, non-placebocontrolled study, it is not possible to know whether the more advanced stages were actually improved by D-penicillamine, such that eventual vision outcome is better. As the present dosing schedule reduced mild ROP, and as no short-term toxicity was observed, perhaps future studies should consider a higher dose or a longer dosing period, particularly among those at the highest risk for developing advanced stages of ROP (the most immature subjects). Severe ROP among the most immature preterm neonates might arise from mechanisms that are different from those that give rise to mild and transient ROP. For instance, as outlined recently by Flynn and Chan-Ling, 29 a disturbance in vasculogenesis (de novo formation of new vessels by transformation of vascular precursor cells) can result in very different outcomes than a disturbance in angiogenesis (budding from existing vessels). They postulate that when the vasculogenic process is perturbed, it can result in posterior disease, with a poorer response to therapy and poorer visual outcome. However, when angiogenesis is perturbed, probably in the larger and more mature preterm neonates, a much better outcome is expected. This theory is concordant with the observation that vasculogenesis is not VEGF-dependent, whereas angiogenesis is. 30 Thus, perhaps VEGF inhibition by Dpenicillamine is better suited to reducing angiogenic disturbances, thereby eliminating only the milder forms of ROP. This is also concordant with the observation of May et al, 31 that VEGF likely plays a role in stimulating angiogenesis in the early part of phase II of ROP.
The potential toxicities of D-penicillamine in premature neonates are a concern. D-Penicillamine reduces the bioavailability of VEGF, 18 and VEGF likely plays a role in stimulating neovascularization in the early part of phase II of ROP. 31 However, VEGF has many important actions during development; thus, reducing its availability may have unwanted consequences. For instance, VEGF is involved in pulmonary microvascular development and inhibiting VEGF might reduce lung function or necessitate prolonged dependence on supplemental oxygen. 32 Inhibiting VEGF might also compromise growth and development of skeletal muscle and other tissues during a critical period, thus inhibiting somatic growth and limiting weight gain. 33 In adults with rheumatic or autoimmune disorders who take D-penicillamine chronically, cytopenias and renal and hepatic toxicity have been described. 34 It is encouraging that Vekerdy-Lakatos et al. 35 observed no significant toxicity of 14-day courses of D-penicillamine given intravenously to over 100 preterm neonates. In fact, in their study, the survival rates and the rates of survival without major or minor impairments, as well as the ROP rates, were significantly better among the D-penicillamine recipients than among the controls. However, no patients born at 22-to 24-week gestation were part of those studies. It is also encouraging that in the present study we did not observe more need for supplemental oxygen at hospital discharge, a lower rate of weight gain at intervals during the NICU stay, a higher than expected rate of cytopenias or elevated serum creatinine or bilirubin in our D-penicillamine recipients. Clearly, it will take large multicentered, randomized, placebo-controlled trials to estimate accurately the adverse effects and the benefits of a course of D-penicillamine for preterm neonates at risk for developing ROP. 18 On the basis of the present results, we speculate that D-penicillamine administration alone will be at most a partial solution to preventing ROP. We speculate that either extended dosing or other approaches, perhaps using combinations of prophylactic methods, will be needed to reduce significantly the incidence of the most severe, vision-threatening, stages of ROP.
